Treatment of PH With Angiotensin II Receptor Blocker and Neprilysin Inhibitor in HFpEF Patients With CardioMEMS Device
Status:
Completed
Trial end date:
2021-09-20
Target enrollment:
Participant gender:
Summary
This study will assess the impact of sacubitril/valsartan on elevated pulmonary artery (PA)
pressures in patients with heart failure (HF) with preserved ejection fraction (HFpEF),
measured using a previously implanted hemodynamic monitoring device (CardioMEMS).
Phase:
Phase 3
Details
Lead Sponsor:
Germans Trias i Pujol Hospital
Treatments:
LCZ 696 Sacubitril and valsartan sodium hydrate drug combination Valsartan